Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our P/B Growth Investor model based on the published strategy of ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $821.67. Easily identify stocks ...

Weinand recommends investing in UnitedHealth Group (UNH), as the company is trading at an attractive P/E ratio. He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...